I-World Health Organization (WHO) imemezele namuhla ukuthi i-GlaxoSmithKline (GSK) izovuselela ukuzibophezela kwayo ekunikeleni ngomuthi wokubulala izikelemu i-albendazole kuze kube sekuqedwe ukuqedwa kwe-lymphatic filariasis njengenkinga yezempilo yomphakathi. Ngaphezu kwalokho, ngo-2025, amaphilisi ayizigidi ezingu-200 ngonyaka wokwelapha i-STH azonikelwa, futhi ngo-2025, amaphilisi ayizigidi ezi-5 ngonyaka ekwelapheni i-cystic echinococcosis.
Lesi simemezelo sakamuva sakhela phezu kwesibopho senkampani seminyaka engama-23 sokulwa neZifo ezintathu Ezinganakekelwa ZaseTropical (NTDs) ezihlukumeza kakhulu eminye yemiphakathi empofu kakhulu emhlabeni.
Lezi zibopho ziyingxenye nje yokuzibophezela okuhlaba umxhwele okwenziwa yi-GSK namuhla eNgqungqutheleni Yezifo Ezithathelwana Ngomalaleveva Nezinganakiwe e-Kigali, lapho bamemezele khona utshalomali oluyisigidigidi esingu-£1 eminyakeni eyi-10 ukuze kusheshiswe inqubekelaphambili ezifweni ezithathelwanayo. - amazwe engenayo. Isitatimende sephephandaba).
Ucwaningo luzogxila emithini emisha eyimpumelelo kanye nemigomo yokuvimbela nokwelapha umalaleveva, isifo sofuba, i-HIV (nge-ViiV Healthcare) kanye nezifo ezinganakiwe zasezindaweni ezishisayo, futhi kubhekwane nokumelana nama-antimicrobial, okuqhubeka nokuthinta abantu abasengozini kakhulu futhi kubangela ukufa kwabantu abaningi. . Umthwalo wezifo emazweni amaningi anemali ephansi udlula ama-60%.